Showing 2644 results
- Media Release /In the largest and longest-running prospective trial in advanced SM, 60% of patients achieved complete or partial resolution of organ damage[1] Advanced SM is rare and has a poor prognosis[…
- Media Release /Global survey of over 8,300 people with moderate-to-severe psoriasis is the first to look at perceptions of clear skin[1] Nearly half (45%) have been asked if they are contagious while 55% do not…
- Media Release /Agreement is the latest in a series of acquisitions and strategic collaborations that have bolstered Novartis' deep and diverse immuno-oncology pipeline Collaboration will co-develop Xencor's…
- Media Release /Findings are first to quantify magnitude of potential survival benefits if Entresto were prescribed to all eligible US HFrEF patients (as defined by authors) [1] Cardiology experts…
- Media Release /Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates…
- Media Release /Novartis wird die Entwicklung des Malariapräparats KAF156 mit wissenschaftlicher und finanzieller Unterstützung von Medicines for Malaria Venture in Zusammenarbeit mit der Bill & Melinda Gates…
- Media Release /Novartis dirigera le développement de la molécule antipaludique KAF156 avec le soutien scientifique et financier de Medicines for Malaria Venture et en collaboration avec la Fondation Bill &…
- Media Release /Fortifying Heart Failure clinical evidence and patient quality of life (FortiHFy) is an umbrella clinical program comprising over 40 active or planned trials The global clinical program…
- Media Release /First data from two treatment-free remission (TFR) studies of Ph+ CML patients treated with Tasigna® both in front-line and second-line following Glivec®* First genomic analysis and 3-year…
- Statement /
Pagination
- ‹ Previous page
- 1
- …
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- …
- 265
- › Next page